Business Context and Reporting Period
This Form 8-K filing by Curis, Inc. (Delaware) was submitted on May 16, 2008. The report discloses the approval of a 2008 cash incentive plan for executive officers by the compensation committee of the board of directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on executive compensation arrangements.
| Executive Officer | 2008 Base Salary | Target Incentive (% of Salary) | Target Cash Incentive Payment |
|---|---|---|---|
| Daniel Passeri | $400,000 | 50% | $200,000 |
| Michael Gray | $300,000 | 35% | $105,000 |
| Changgeng Qian | $250,000 | 30% | $75,000 |
| Mark Noel | $210,000 | 15% | $31,500 |
| Total | $1,160,000 | - | $411,500 |
Material Changes
The primary material change is the establishment of a new 2008 cash incentive plan. This plan replaces or supplements prior arrangements to motivate executives to achieve specific corporate performance objectives for fiscal 2008.
Guidance, Outlook, and Management Commentary
The incentive plan is tied to four equally-weighted corporate goal categories:
- Development goals for CUDC-101 (the company's first drug candidate), including IND filing and clinical trial enrollment.
- Nomination of additional development candidates from targeted cancer programs.
- Establishment of collaborations with specified research funding and payment terms.
- Financial performance objectives, including cash management and capital raising.
Performance Tiers: Payments range from 50% of the target amount (Threshold) to 150% of the target amount (Maximum), with 100% paid at the Target level.
Payment Terms: Awards are generally paid in cash after fiscal year 2008 ends, no later than March 15, 2009. The committee retains discretion to pay in equity under the 2000 Stock Incentive Plan. In the event of a change in control, short-term incentives vest at 100% of the target amount.
Investor Verification Checklist
- Verify the specific milestones for CUDC-101 development and IND filing status.
- Confirm the company's progress on capital raising and cash management objectives.
- Monitor the status of potential collaborations for targeted cancer programs.
- Review the 2000 Stock Incentive Plan terms in case equity is used for compensation.